Abbott MediaRoom http://abbott.mediaroom.com/ Abbott Hosts Conference Call for Second-Quarter Earnings http://abbott.mediaroom.com/2018-06-20-Abbott-Hosts-Conference-Call-for-Second-Quarter-Earnings Wed, 20 Jun 2018 09:00:00 -0400 http://abbott.mediaroom.com/2018-06-20-Abbott-Hosts-Conference-Call-for-Second-Quarter-Earnings Abbott Declares 378th Consecutive Quarterly Dividend http://abbott.mediaroom.com/2018-06-08-Abbott-Declares-378th-Consecutive-Quarterly-Dividend Fri, 08 Jun 2018 10:15:00 -0400 http://abbott.mediaroom.com/2018-06-08-Abbott-Declares-378th-Consecutive-Quarterly-Dividend Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management http://abbott.mediaroom.com/2018-05-31-Abbott-Introduces-the-Afinion-TM-2-Analyzer-Rapid-Test-System-for-Diabetes-Management STATE-OF-THE-ART MULTI-ASSAY TEST SYSTEM HELPS PEOPLE WITH DIABETES GET THE HbA1c RESULTS THEY NEED WITHIN 3 MINUTES -- ALLOWING MORE TIME FOR CONSULTATION AND CARE DURING A SINGLE HEALTHCARE VISIT Thu, 31 May 2018 08:00:00 -0400 http://abbott.mediaroom.com/2018-05-31-Abbott-Introduces-the-Afinion-TM-2-Analyzer-Rapid-Test-System-for-Diabetes-Management Real-World Study Results Support Use of Abbott's AMPLATZER™ Amulet™ to Reduce Stroke in Patients Suffering from Atrial Fibrillation Without the Need for Lifetime Blood Thinners http://abbott.mediaroom.com/2018-05-24-Real-World-Study-Results-Support-Use-of-Abbotts-Amplatzer-Amulet-to-Reduce-Stroke-in-Patients-Suffering-From-Atrial-Fibrillation-Without-Need-For-Lifetime-Blood-Thinners - Study confirms safety of treatment with AMPLATZER Amulet device and reduction in stroke risk by nearly 60 percent Thu, 24 May 2018 09:59:00 -0400 http://abbott.mediaroom.com/2018-05-24-Real-World-Study-Results-Support-Use-of-Abbotts-Amplatzer-Amulet-to-Reduce-Stroke-in-Patients-Suffering-From-Atrial-Fibrillation-Without-Need-For-Lifetime-Blood-Thinners Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease http://abbott.mediaroom.com/2018-05-23-Newest-Generation-of-Leading-Heart-Stent-is-Now-Approved-in-the-U-S-for-People-with-Coronary-Artery-Disease - XIENCE Sierra™, the newest generation of XIENCE drug-eluting stents, received U.S. Food and Drug Administration (FDA) approval Wed, 23 May 2018 09:00:00 -0400 http://abbott.mediaroom.com/2018-05-23-Newest-Generation-of-Leading-Heart-Stent-is-Now-Approved-in-the-U-S-for-People-with-Coronary-Artery-Disease